40321-86-6

40321-86-6 structure

Name: niclosamide sodium salt
Chemical Name: niclosamide sodium salt
CAS Number: 40321-86-6
Molecular Formula: C₁₃H₇Cl₂N₂NaO₄
Molecular Weight: 349.10100
Catalog: Signaling Pathways JAK/STAT Signaling STAT
Create Date: 2018-04-18 08:57:37
Modify Date: 2025-08-24 22:34:54
Niclosamide (BAY2353) sodium is an orally active antihelminthic agent used in parasitic infection research[1]. Niclosamide sodium is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells[4]. Niclosamide sodium has biological activities against cancer, and inhibits DNA replication in Vero E6 cells[2][3][5].

Name	niclosamide sodium salt

Description	Niclosamide (BAY2353) sodium is an orally active antihelminthic agent used in parasitic infection research[1]. Niclosamide sodium is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells[4]. Niclosamide sodium has biological activities against cancer, and inhibits DNA replication in Vero E6 cells[2][3][5].
Related Catalog	Signaling Pathways >> Stem Cell/Wnt >> STAT Research Areas >> Cancer Research Areas >> Infection Signaling Pathways >> JAK/STAT Signaling >> STAT
In Vitro	Niclosamide sodium (0.6 nM-46 µM) treatment inhibits adrenocortical carcinoma cellular proliferation in BD140A, SW-13, and NCI-H295R cells[3]. Niclosamide sodium (0.05-5 μM, 24 h) treatment inhibits STAT3-mediated luciferase reporter activity in HeLa cells[4]. Niclosamide sodium (10 μM) treatment inhibits virus replication in Vero E6 cells[5]. Cell Viability Assay[3] Cell Line: BD140A, SW-13 and NCI-H295R cells Concentration: 0.6 nM-46 µM Incubation Time: Result: Inhibited cellular proliferation in adrenocortical carcinoma cell lines with the IC50 of 0.12 µM, 0.15 µM, and 0.53 µM in BD140A, SW-13, and NCI-H295R, respectively. Cell Viability Assay[4] Cell Line: Hela cells Concentration: 0.05-5 μM Incubation Time: 24 hours Result: Inhibited STAT3-mediated luciferase reporter activity with an IC50 of 0.25 μM. Western Blot Analysis[5] Cell Line: Vero E6 cells Concentration: 10 μM Incubation Time: 2 days Result: Inhibited the synthesis of viral antigens of SARS-CoV in Vero E6 cells.
In Vivo	Niclosamide sodium (oral gavage; 100 mg/kg, 200 mg/kg; once a week; 8 weeks) treatment inhibits adrenocortical carcinoma tumor growth in vivo[3]. Animal Model: Nu+/Nu+ mice injected with NCI-H295R cells[3] Dosage: 100 mg/kg, 200 mg/kg Administration: Oral gavage; 100 mg/kg, 200 mg/kg; once a week; 8 weeks Result: Showed a 60%-80% inhibition in tumor growth, as compared to the control group.
References	[1]. P Andrews, et al. The biology and toxicology of molluscicides, Bayluscide. Pharmacol Ther. 1982;19(2):245-95. [2]. Wei Chen, et al. Niclosamide: Beyond an antihelminthic drug. Cell Signal. 2018 Jan;41:89-96. [3]. Kei Satoh, et al. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma. Clin Cancer Res. 2016 Jul 15;22(14):3458-66. [4]. Xiaomei Ren, et al. Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway. ACS Med Chem Lett. 2010 Sep 7;1(9):454-9. [5]. Chang-Jer Wu, et al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob Agents Chemother. 2004 Jul;48(7):2693-6.

Molecular Formula	C₁₃H₇Cl₂N₂NaO₄
Molecular Weight	349.10100
Exact Mass	347.96800
PSA	97.98000
LogP	4.89390

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

40321-86-6	9085-26-1
71119-23-8	54524-32-2
62696-99-5	23255-99-4
127373-66-4	87713-30-2
68244-58-6	18763-65-0
591228-13-6	148320-21-2
78800-37-0	874361-16-7
61941-58-0	78879-25-1
760-00-9	2420-18-0
78912-10-4	79179-46-7